AVEO Oncology is passionate in our pursuit of improving the lives of patients with cancer.
Find out More
A Phase 3 Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced RCC
Click here for more information
2016 JMP Securities Life Science Conference
June 22, 2016
28th Annual ROTH Conference
March 16, 2016
AVEO to Present at the 2016 JMP Securities Life Science Conference
June 15, 2016
AVEO Announces Dosing of First Patient in the Pivotal Phase 3 TIVO-3 Study of Tivozanib in Renal Cell Carcinoma
May 26, 2016
AVEO Announces Closing of Private Placement and Amended Term Loan to Fund Pivotal TIVO-3 Trial and Combination PD-1 Trial of Tivozanib in Renal Cell Cancer
May 18, 2016
© 2016 AVEO Pharmaceuticals, Inc. All rights reserved.